SourceBio International (LON:SBS) has made a huge impact on its return to public markets. It reported a 139% rise in fiscal 2020 (FY20) reported revenues to £50.7mln from £21.2mln and underlying earnings (EBITDA) of £14mln, vs £3mln in FY19. Proactive Analyst Emma Ulker explains why this growth has been driven largely on its rapid mobilisation of resources to create a new fourth division; infectious disease testing services.
Click here to read Emma Ulker's initiation report on SourceBio